Investors
We are committed to creating value for our society and our shareholders through life-changing peptide therapeutics for people who need them.
-
Share price information
ZEAL (COP)
769.50DKKZealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL. Access investor information including full share price in DKK plus investor tools.
More Stock information -
Annual report 2023
-
Corporate presentation
Catch up on our past events
View the webcasts and documents from our past events here
76%
of our operating expenditure focused on R&D in 2023
12
analysts covering Zealand Pharma
71.0m
shares outstanding as of September 30, 2024
300+
employees in Denmark and the United States
Q3 2024 Interim Report
Latest financial report
On November 7, 2024, Zealand Pharma reported interim results for the quarter and nine months ended September 30, 2024 and provided a company update.
Latest news
Newsroom-
Zealand Pharma to participate in the Jefferies London Healthcare Conference
READ MORE -
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
READ MORE -
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
READ MORE -
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
READ MORE
Stay up-to-date with the latest news from Zealand
Sign up to receive press releases and important company announcements directly to your inbox
-
Corporate governance
At Zealand Pharma, our corporate governance structure aims to support long-term financial performance, meet the obligations of our stakeholders, and create value for shareholders and society.
-
Annual general meeting
The Annual General Meeting for 2024 was held on Wednesday, March 20th, 2024 at 15:00 CET. Find additional information and the webcast recording on the AGM page.
-
Analyst coverage
Zealand Pharma is currently covered by 12 analysts and financial institutions across the U.S and Europe.
Safety, tolerability, and clinical effects of ZP8396, an amylin analog
Featured publications
Results from a 6-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in October 2024.
An innovative R&D pipeline
More investor information
Investor relations policy
We are committed to providing reliable and transparent information about our business, development programs and scientific results in a clear and timely manner.
Prospectus
Read our latest prospectus and prospectus summary from April 3, 2023.
Investor and Media contacts
